Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity

Valeant press release ---- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Salix, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders, today announced that it has rapidly scaled up its sales force by nearly 40 percent, effective immediately. "This is a demonstration of our commitment to GI and its relative importance to the broader value of our company," said Joseph C. Papa, Chairman and CEO of Valeant. "The significant investments in Salix's dedicated Primary Care Physician (PCP) sales force will help us further reach patients in need of irritable bowel syndrome with diarrhea (IBS-D) treatment, and in doing so, will further accelerate growth for our company." To learn more about Valeant deployment of expanded Salix sales force to capture untapped market opportunity click on the picture below to read the release.